BPC-157 is a synthetic chain of fifteen amino acids based on a fragment of a protein found in human gastric juice. Almost everything known about it comes from rats. It holds no UK marketing authorisation, is not a permitted supplement ingredient, and is prohibited in sport under WADA category S0.
This is a research summary, not a how-to. You will not find a dose here, or a supplier, because neither exists in a form anyone can responsibly publish. What follows is what the studies measured, in which species, and what the regulator says. More than 30 years of research have produced exactly 1 clinical study that a systematic review was willing to include.
If you have arrived here because a podcast, a gym or a clinic mentioned this peptide, the useful question is not whether it works. It is how much of the evidence was ever collected in a human being.
What is BPC-157?
BPC stands for Body Protection Compound. In the early 1990s a Zagreb research group isolated a large protective protein from human gastric juice and identified an active fragment within it. BPC-157 is the synthetic version of that fragment: fifteen amino acids, sequence GEPPPGKPADDAGLV, made in a laboratory rather than extracted. A peptide is only a short chain of the ordinary amino acids that arrive in food; the sequence and the length are what make this one a research compound rather than a nutrient.
The compound also carries the code PL 14736, from a pharmaceutical development programme that took an oral form into trials for inflammatory bowel disease more than 20 years ago. That programme never produced a licensed product, which is a detail worth holding on to: the molecule is neither new nor undiscovered by the industry.
The peptide is unusually stable in gastric acid, which is why an oral form is discussed at all. Most peptides are destroyed in the stomach within minutes. That stability is the genuinely interesting property here, and it is well documented.
What does BPC-157 do in the body?
Every mechanism below was established in cells or in animals, across roughly 35 studies. None has been confirmed in a human trial, and the wording matters: these are proposed pathways, not demonstrated clinical effects.
The most consistently reported action is on new blood vessel growth. Reviews describe increased signalling through VEGFR2 and nitric oxide production via the Akt and eNOS route, which in animal wounds means more capillaries reaching the injured area. Poorly supplied tissue, such as the mid-portion of a tendon, is exactly where that would matter if it translated.
A second strand concerns the cells that build connective tissue, the fibroblasts that lay down the collagen a tendon is largely made of. Chang and colleagues reported that BPC-157 increased outgrowth, survival and migration of tendon fibroblasts in rats, and in later work that it raised expression of the growth hormone receptor on those same cells. A third strand is anti-inflammatory: reduced inflammatory cytokines in animal models, which is the mechanism people have in mind when they compare it with an everyday anti-inflammatory approach. The comparison does not hold, because one is a food supplement sold legally and the other is not.
The gastric findings are older and broader. In rat models the peptide protected the stomach lining against alcohol and anti-inflammatory drug damage, which is where the whole line of research began.
How much of this was tested in people?
Here is the number that changes how you read everything else.
A systematic review published in the HSS Journal in 2025 searched PubMed, Cochrane and Embase from database inception to June 2024, covering work published over 31 years. Screening left 36 studies. Of those, 35 studies were preclinical, in animals or cells, and 1 study was clinical.
THE BPC-157 LITERATURE, AS COUNTED BY A 2025 SYSTEMATIC REVIEW
A separate scoping review the same year put it slightly differently and reached the same place: 3 pilot studies in humans exist, covering intra-articular knee pain, interstitial cystitis, and intravenous safety and pharmacokinetics. No adverse effects were reported in them. Between them they are smaller than a single ward round.
Relief lasting more than 6 months in 7 of 12 patients is not nothing. That study was also a retrospective look at people who chose the treatment, with no control group, no blinding and no imaging endpoint. Such a design cannot separate the peptide from time, from the injection itself, or from expectation.
WHERE BPC-157 SITS ON THE EVIDENCE LADDER
animal work
(BPC-157 is here)
pilot studies
phase II
marketing
authorisation
What the animal studies actually found
Dismissing preclinical work would be as unfair as overselling it. The animal literature is consistent across laboratories and across injury types, which is more than can be said for many compounds. The table sets out what was done, and in what species.
| Study | Model | What was measured |
|---|---|---|
| Chang et al., 2011 | Rat Achilles tendon and cultured tendon fibroblasts | Tendon outgrowth, cell survival and cell migration all increased |
| Chang et al., 2014 | Rat tendon fibroblasts in culture | Growth hormone receptor expression raised |
| Cerovecki et al., 2010 | Transected medial collateral ligament in rats | Improved biomechanical and functional healing |
| Vasireddi et al., 2025 | Systematic review, 36 studies | Improved outcomes across muscle, tendon, ligament and bone in animals |
| McGuire et al., 2025 | Scoping review, human and animal | VEGFR2 and Akt-eNOS signalling, three human pilot studies only |
Rat tendon is not human tendon. Rodents heal connective tissue faster, the injuries are surgically standardised rather than degenerative, follow-up runs to 2 or 4 weeks rather than years, and the animal does not have to return to five-a-side. Compounds that repaired rat tissue and then failed in people are a long list, not an exception.
Side effects, and why nobody can list them properly
The honest answer to what are the side effects is that the studies capable of finding them have not been done. The 2025 systematic review states the position in four words: no clinical safety data.
Across the handful of human pilot studies, no adverse effects were reported. That sentence gets quoted as reassurance, and it is not one. Three small studies without a control group cannot detect an uncommon harm, a delayed harm, or anything that needed a blood test nobody ordered. Preclinical toxicology in animals found no organ damage, which tells you about rats.
Two specific concerns come up repeatedly and deserve straight answers. On the liver: the peptide is metabolised there, has a half-life of under 30 minutes and is cleared by the kidneys, and no case of liver injury has been formally attributed to it, but no systematic hepatic safety study exists either. On cancer risk: promoting new blood vessel growth is a mechanism that would need evaluating in anyone with a current or past malignancy, and that evaluation has not been published.
Then there is what is in the vial. Because supply sits outside the medicines regime, nothing guarantees identity, purity, sterility or the stated quantity. Analyses of research-labelled peptides sold online have repeatedly found products that were underdosed, contaminated or a different compound entirely. That risk is separate from the molecule, and it is the one an individual buyer has no way to check.
You will notice this article has not given a dose. The 2026 biopharmaceutical review is explicit that no validated dosing regimen exists after 30 years of study, and the figures circulating in forums are extrapolated from rats by body weight, which is not how human dosing is established.
Is BPC-157 legal in the UK?
The position has three layers, and conflating them is where most of the confusion comes from.
As a medicine, BPC-157 holds no marketing authorisation from the MHRA for any indication. It cannot be prescribed on the NHS, and no licensed product containing it exists in Great Britain.
As a food supplement, BPC-157 is not permitted. A synthetic peptide with no history of significant consumption in Great Britain before 1997 falls into novel food territory, and no authorisation has been granted. The compound carries no entry on the GB Nutrition and Health Claims Register either, so no health claim may lawfully be made for it.
As a research chemical, it is sold. BPC-157 is not a controlled drug, and UK websites supply vials labelled for laboratory use and not for human consumption, at around 100 pounds. Under the Human Medicines Regulations 2012, what makes something a medicinal product includes how it is presented and what it is intended for, so a research-use label does not by itself settle the question. For a position you can rely on, ask a solicitor rather than a blog.
TWO SENTENCES THAT ARE BOTH TRUE
WHAT THE SELLERS SAY
- “Legal to buy and possess in the UK for laboratory research purposes.”
- Accurate as far as it goes: the compound is not a controlled drug.
- It says nothing about whether the product is fit to put in a person.
WHAT THE REGULATORS SAY
- No MHRA marketing authorisation, for any indication.
- Not an authorised novel food, so not lawful in a supplement.
- Prohibited in sport at all times under WADA category S0.
Prohibited in sport, at all times
If you compete under any body that follows the World Anti-Doping Code, this section settles the matter for you. BPC-157 falls under S0, Non-Approved Substances, which covers compounds not approved for human therapeutic use by any governmental health authority. S0 substances are banned in competition and out of competition, with no threshold and no exemption route through ordinary use. That is a different section of the list from TB-500, which sits under S2.3 as thymosin beta-4 and its derivatives, and the difference is not cosmetic: everything in S0 is a Specified Substance and everything in S2 is not, which changes what an athlete has to prove. Standard sanctions for such a finding run to 4 years.
That reach is wider than elite sport. UK Anti-Doping tests across many funded sports, and the code applies to club and masters athletes in affiliated competition. Athletes have been sanctioned for BPC-157 findings, and methods able to detect the peptide in urine for at least 72 hours were published in 2016.
Strict liability applies. An athlete is responsible for what is in their sample, whatever a supplement label said, and a contaminated product is not a defence that removes the finding.
If you are here because a tendon or your gut is not healing
Most people who search this peptide are not curious about pharmacology. They have had an Achilles or an elbow that has hurt for 8 months, or a gut that flares whatever they eat, and conventional care has been slow.
For tendon problems, the intervention with genuine randomised support is progressive loading, prescribed and supervised, over 12 weeks or more. Unglamorous, effective, and available through NHS musculoskeletal physiotherapy, with self-referral in many areas. Anything you take alongside that programme, including a supplement aimed at tendon comfort, sits beside that programme rather than replacing it.
For persistent gut symptoms, the priority is a diagnosis. Coeliac disease, inflammatory bowel disease and infection all have specific treatments and specific tests, and all can sit behind symptoms that look like a leaky gut narrative online. Blood in the stool, unintended weight loss or a change in bowel habit lasting more than 3 weeks needs a GP appointment now, not a peptide.
None of this means BPC-157 will turn out to be useless. It means the case for it is currently made in rats, the supply chain is unregulated, and the people telling you it works are rarely the people who would carry the consequences if it does not.
Frequently asked questions
What does BPC-157 do to your body?
In animal models it increases new blood vessel formation through VEGFR2 and nitric oxide signalling, raises tendon fibroblast activity, and reduces inflammatory cytokines. All of that is preclinical. A 2025 systematic review found 35 studies in animals or cells against 1 study in patients, so what it does in people is largely unmeasured.
What are the negative effects of BPC-157?
No adverse effects were reported in the three small human pilot studies, but those studies are far too small to find uncommon or delayed harms. There is no published toxicology programme in humans. A separate risk comes from the supply chain, where purity, identity and sterility are not guaranteed.
Can BPC-157 cause liver damage?
The peptide is metabolised in the liver and has a short half-life, and no case of liver injury has been formally attributed to it in the published literature. Clearance takes under 30 minutes and runs through the kidneys. That is not the same as evidence of safety: no systematic hepatic safety study has been conducted, so the question is open rather than answered.
Is BPC-157 legal in the UK?
It is not a controlled drug, and it is sold in the UK labelled for laboratory research. There is no MHRA marketing authorisation, and it is not an authorised ingredient in food supplements. Under the Human Medicines Regulations 2012, presentation and intended use help decide whether a product counts as a medicine.
Is BPC-157 available on the NHS?
No. No licensed product containing BPC-157 exists in Great Britain, so it cannot be prescribed on the NHS or privately. Clinics offering it work outside the licensed medicines route, and the usual protections that come with an authorised medicine do not apply.
Is BPC-157 banned in sport?
Yes. It is prohibited under category S0, Non-Approved Substances, of the WADA Prohibited List, which means banned in competition and out of competition. Strict liability applies, so an athlete is responsible for a positive finding regardless of what a product label claimed. Sanctions reach 4 years.
What is the difference between BPC-157 and TB-500?
They are different peptides with different origins: BPC-157 comes from a gastric protein fragment, TB-500 from thymosin beta-4. Their regulatory position in Great Britain is identical. Neither is an authorised medicine or a permitted supplement ingredient, and both sit under WADA category S0.
Sources
- Vasireddi N., Hahamyan H.A., Salata M.J., et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal, 2025. DOI: 10.1177/15563316251355551
- McGuire F.P., Martinez A., Lenz C.G., Skinner J., Cushman D.M. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 2025. DOI: 10.1007/s12178-025-09990-7
- Chang C.H., Tsai W.C., Lin M.S., Hsu Y.H., Pang J.H.S. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011. DOI: 10.1152/japplphysiol.00945.2010
- Chang C.H., Tsai W.C., Hsu Y.H., Pang J.H.S. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 2014. DOI: 10.3390/molecules191119066
- Cerovecki T., Bojanic I., Brcic L., et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research, 2010. DOI: 10.1002/jor.21107
- BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational barriers. Pharmaceutics, 2026. DOI: 10.3390/pharmaceutics18050625
This article describes published research and the regulatory position in Great Britain. It is not medical advice, not legal advice, and not a recommendation to use BPC-157. Speak to your GP about persistent tendon or gut symptoms, and to a physiotherapist about a loading programme.
